During the last session, AIM ImmunoTech Inc (AMEX:AIM)’s traded shares were 0.41 million, with the beta value of the company hitting 0.75. At the end of the trading day, the stock’s price was $0.12, reflecting an intraday loss of -5.39% or -$0.01. The 52-week high for the AIM share is $0.62, that puts it down -416.67 from that peak though still a striking 8.33% gain since the share price plummeted to a 52-week low of $0.11. The company’s market capitalization is $8.32M, and the average intraday trading volume over the past 10 days was 0.3 million shares, and the average trade volume was 1.06 million shares over the past three months.
AIM ImmunoTech Inc (AIM) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. AIM has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.09.
AIM ImmunoTech Inc (AMEX:AIM) trade information
AIM ImmunoTech Inc (AIM) registered a -5.39% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -5.39% in intraday trading to $0.12, hitting a weekly high. The stock’s 5-day price performance is -14.79%, and it has moved by -5.39% in 30 days. Based on these gigs, the overall price performance for the year is -72.44%. The short interest in AIM ImmunoTech Inc (AMEX:AIM) is 3.17 million shares and it means that shorts have 3.1 day(s) to cover.
AIM ImmunoTech Inc (AIM) estimates and forecasts
In the rating firms’ projections, revenue will increase 1,429.41% compared to the previous financial year.
Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 100k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 40k and 50k respectively. In this case, analysts expect current quarter sales to shrink by -100.00% and then jump by 100.00% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 34.59%.
AIM Dividends
AIM ImmunoTech Inc is due to release its next quarterly earnings on 2025-Mar-26. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
AIM ImmunoTech Inc (AMEX:AIM)’s Major holders
AIM ImmunoTech Inc insiders own 10.32% of total outstanding shares while institutional holders control 12.54%, with the float percentage being 13.98%. ARMISTICE CAPITAL, LLC is the largest shareholder of the company, while 36.0 institutions own stock in it. As of 2024-06-30, the company held over 4.08 million shares (or 7.718% of all shares), a total value of $1.52 million in shares.
The next largest institutional holding, with 1.99 million shares, is of VANGUARD GROUP INC’s that is approximately 4.021% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $0.74 million.
Also, the Mutual Funds coming in first place with the largest holdings of AIM ImmunoTech Inc (AIM) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 1.31 shares. This amounts to just over 1.91 percent of the company’s overall shares, with a $0.16 million market value. The same data shows that the other fund manager holds slightly less at 620.23, or about 0.90% of the stock, which is worth about $75047.0.
